AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study

Why It Matters

The OS miss raises questions about the durability of Epkinly’s accelerated approval, yet its PFS advantage and upcoming frontline data keep it central to AbbVie’s oncology growth strategy.

Key Takeaways

• OS improvement 4%, not statistically significant
• PFS risk reduced 26% versus chemotherapy
• Accelerated approval likely retained despite OS miss
• Frontline trial readouts expected 2026
• Additional Phase III combos progressing, results due this year

Pulse Analysis

Bispecific antibodies like Epkinly are reshaping the lymphoma landscape by simultaneously engaging T‑cells and tumor antigens. Since its accelerated approval in May 2023, Epkinly has been positioned as a targeted option for patients who cannot tolerate high‑dose chemotherapy or stem‑cell transplantation. The drug’s mechanism—CD3×CD20 engagement—offers a novel immunologic approach that differentiates it from traditional chemo‑immunotherapy, attracting significant investor interest and prompting multiple late‑stage trials across various combinations.

The EPCORE DLBCL‑1 topline data present a mixed picture. While the primary overall survival endpoint fell short of statistical significance, the trial recorded a modest 4% absolute OS gain and a robust 26% hazard reduction in progression‑free survival. These efficacy signals, coupled with higher complete response rates and longer duration of response, suggest clinical benefit that may satisfy regulators despite the OS miss. The FDA’s focus on overall survival as a primary endpoint adds pressure, but the accelerated approval pathway allows continuation pending confirmatory evidence, which analysts believe remains likely.

Looking ahead, AbbVie and Genmab have two additional Phase III studies—EPCORE‑DLBCL‑4 with lenalidomide and EPCORE‑DLBCL‑2 combined with R‑CHOP—scheduled for readouts this year. Positive outcomes could reinforce the drug’s value proposition and support its frontline positioning slated for 2026. Investor sentiment remains cautiously optimistic, reflecting confidence that Epkinly’s broader data package will mitigate the current OS shortfall and sustain its role in the competitive DLBCL market.